Intrastromal Injection of Bevacizumab in the Management of Corneal Neovascularization: About 25 Eyes
Introduction. Corneal neovessels are a major risk factor for corneal graft rejection, due to the loss of the immune privilege. The purpose of this study is to evaluate the effectiveness of intrastromal injection of bevacizumab in the treatment of corneal neovascularization. Material and Methods. Thi...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2016/6084270 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832550226599084032 |
|---|---|
| author | Belghmaidi Sarah Hajji Ibtissam Baali Mohammed Soummane Hasna Moutaouakil Abdeljalil |
| author_facet | Belghmaidi Sarah Hajji Ibtissam Baali Mohammed Soummane Hasna Moutaouakil Abdeljalil |
| author_sort | Belghmaidi Sarah |
| collection | DOAJ |
| description | Introduction. Corneal neovessels are a major risk factor for corneal graft rejection, due to the loss of the immune privilege. The purpose of this study is to evaluate the effectiveness of intrastromal injection of bevacizumab in the treatment of corneal neovascularization. Material and Methods. This is a prospective study that included 25 eyes of 22 patients with deep corneal neovessels, treated with intrastromal injections of bevacizumab. Results. The average age of patients was 31 years ranging from 16 to 44 years. The causes of neovascularization were dominated by herpetic keratitis (10 cases). The evolution was marked by complete regress of neovessels in 16 patients, partial regress in 6 cases, and reduced opacity and improved visual acuity in 5 patients. No side effects were noted. Discussion. Short-term results demonstrated the effectiveness of intrastromal injection of bevacizumab in the treatment of corneal neovessels. It may be an option or a complement to other useful treatments in stabilizing or improving vision. Conclusion. Bevacizumab is an effective additional treatment for the improvement of corneal transplants prognosis with preoperative corneal neovascularization. |
| format | Article |
| id | doaj-art-8fad3f2079164030a58b69a413a23467 |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-8fad3f2079164030a58b69a413a234672025-02-03T06:07:18ZengWileyJournal of Ophthalmology2090-004X2090-00582016-01-01201610.1155/2016/60842706084270Intrastromal Injection of Bevacizumab in the Management of Corneal Neovascularization: About 25 EyesBelghmaidi Sarah0Hajji Ibtissam1Baali Mohammed2Soummane Hasna3Moutaouakil Abdeljalil4Ophthalmology Department, Mohammed VI University Hospital, 40000 Marrakech, MoroccoOphthalmology Department, Mohammed VI University Hospital, 40000 Marrakech, MoroccoOphthalmology Department, Mohammed VI University Hospital, 40000 Marrakech, MoroccoOphthalmology Department, Mohammed VI University Hospital, 40000 Marrakech, MoroccoOphthalmology Department, Mohammed VI University Hospital, 40000 Marrakech, MoroccoIntroduction. Corneal neovessels are a major risk factor for corneal graft rejection, due to the loss of the immune privilege. The purpose of this study is to evaluate the effectiveness of intrastromal injection of bevacizumab in the treatment of corneal neovascularization. Material and Methods. This is a prospective study that included 25 eyes of 22 patients with deep corneal neovessels, treated with intrastromal injections of bevacizumab. Results. The average age of patients was 31 years ranging from 16 to 44 years. The causes of neovascularization were dominated by herpetic keratitis (10 cases). The evolution was marked by complete regress of neovessels in 16 patients, partial regress in 6 cases, and reduced opacity and improved visual acuity in 5 patients. No side effects were noted. Discussion. Short-term results demonstrated the effectiveness of intrastromal injection of bevacizumab in the treatment of corneal neovessels. It may be an option or a complement to other useful treatments in stabilizing or improving vision. Conclusion. Bevacizumab is an effective additional treatment for the improvement of corneal transplants prognosis with preoperative corneal neovascularization.http://dx.doi.org/10.1155/2016/6084270 |
| spellingShingle | Belghmaidi Sarah Hajji Ibtissam Baali Mohammed Soummane Hasna Moutaouakil Abdeljalil Intrastromal Injection of Bevacizumab in the Management of Corneal Neovascularization: About 25 Eyes Journal of Ophthalmology |
| title | Intrastromal Injection of Bevacizumab in the Management of Corneal Neovascularization: About 25 Eyes |
| title_full | Intrastromal Injection of Bevacizumab in the Management of Corneal Neovascularization: About 25 Eyes |
| title_fullStr | Intrastromal Injection of Bevacizumab in the Management of Corneal Neovascularization: About 25 Eyes |
| title_full_unstemmed | Intrastromal Injection of Bevacizumab in the Management of Corneal Neovascularization: About 25 Eyes |
| title_short | Intrastromal Injection of Bevacizumab in the Management of Corneal Neovascularization: About 25 Eyes |
| title_sort | intrastromal injection of bevacizumab in the management of corneal neovascularization about 25 eyes |
| url | http://dx.doi.org/10.1155/2016/6084270 |
| work_keys_str_mv | AT belghmaidisarah intrastromalinjectionofbevacizumabinthemanagementofcornealneovascularizationabout25eyes AT hajjiibtissam intrastromalinjectionofbevacizumabinthemanagementofcornealneovascularizationabout25eyes AT baalimohammed intrastromalinjectionofbevacizumabinthemanagementofcornealneovascularizationabout25eyes AT soummanehasna intrastromalinjectionofbevacizumabinthemanagementofcornealneovascularizationabout25eyes AT moutaouakilabdeljalil intrastromalinjectionofbevacizumabinthemanagementofcornealneovascularizationabout25eyes |